505 results about "Infection risk" patented technology

The present invention comprises methods and apparatuses that can provide measurement of glucose and other analytes with a variety of sensors without many of the performance-degrading problems of conventional approaches. As apparatus according to the present invention comprises a blood access system, adapted to remove blood from a body and infuse at least a portion of the removed blood back into the body. Such an apparatus also comprises an analyte sensor, mounted with the blood access system such that the analyte sensor measures the analyte in the blood that has been removed from the body by the blood access system. A method according to the present invention comprises removing blood from a body, using an analyte sensor to measure an analyte in the removed blood, and infusing at least a portion of the removed blood back into the body. The use of a non-contact sensor with a closed system creates a system will minimal infection risk.

Novel orthopaedic bone screws/spinal pedicle screws and implants that include coatings to help promote a structurally stable interface between the implant and the patient's bone/tissue, and methods of coating such screws and implants are provided. The implants and methodologies described involve at least a coating that facilitates osseous integration, and additionally at least one coating that either reduces the risk of infection in immunologically suppressed patients and/or for utilization in patients who have infection, but who require stabilization, or coatings that permit the use of dissimilar metals and prevent galvanic corrosive reactions.

The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.

The invention discloses a serum-free culture medium for mesenchymal stem cells. The serum-free culture medium for the mesenchymal stem cells comprises the following ingredients: fibronectin at the final concentration of 25mu g/ml, basic fibroblast growth factors at the final concentration of 10ng/ml, human epidermal growth factors at the final concentration of 15ng/ml, recombinant human insulin at the final concentration of 1mg/ml, human transferrin at the final concentration of 0.55mg/ml, human blood albumin in a volume ratio of 5 percent, sodium selenite at the final concentration of 0.67mug/ml, L-carnitine at the final concentration of 5mM and resveratrol at the final concentration of 30mu M. When the mesenchymal stem cells are cultured by the serum-free culture medium for the mesenchymal stem cells, animal-derived serum is not contained, so infection risks can be controlled; the L-carnitine and the resveratrol which are added into the serum-free culture medium for the mesenchymalstem cells can effectively improve the growth state of the mesenchymal stem cells; and the growth speed of the mesenchymal stem cells is remarkably improved, and the biological characteristics of themesenchymal stem cells are kept unchanged.

The invention discloses a brown yogurt and a preparation method thereof; each 1000 mL of the brown yogurt comprises the following components: 80-130 g of milk powder, 1-20 g of concentrated whey protein powder, 3-20 g of a thickening agent, 20-90 g of white granulated sugar, 0.05-1.5 g of an edible essence, 10-40 g of reducing sugar, 0.1-1 g of pectin, 0.1-0.5 g of an emulsifier, 0.05-0.15 g of lactic acid bacteria, 30-60 g of animal cream, 0.1-1 g of an acidity regulator, and the balance water. The brown yogurt is rich in nutrition, delicate in mouthfeel and unique in flavor; during a Maillard reaction, the pressure is increased, the reaction difficulty is reduced and the energy is saved; and material preparation links are integrated in production, all the raw materials are intensively added before fermentation, production links are reduced, and bacterial infection risks are reduced.

A method and composition for treating enteric pathogen infections in animals suffering from such infections or displaying diseases or conditions consistent with such infections or for preventing or reducing the likelihood of enteric pathogen infections in animals at risk for developing such infections.

Embodiments described herein relates to a platform for infection surveillance that can assist infection preventionists and antimicrobial stewardship teams with infection detection rules and dynamic alerts by aggregating and processing infection surveillance data with contextual healthcare data regarding a facility, organization, and so on. The platform can enable proactive prevention of infection risks by detecting risk patterns in the data and generating alerts.

A device is disclosed which couples the use of Trans Epithelial Nerve Stimulation with the administration of a therapeutic injection, such as an immunization, or tissue sampling procedure such as deriving a blood sample. By such an arrangement the discomfort associated with these procedures may be considerably reduced or eliminated, thereby improving compliance with a range of medical procedures. To date TENS has not been used in such an arrangement, rather development in TENS technology has been aimed at improving its efficacy. Similarly injection technology developments have been orientated around reducing cross infection risks and accidental injury to operator or patient.

The invention provides an umbilic clamping cutter, comprising a pushing and cutting rod, a mother clamp, an infant clamp and a clamp holder, wherein one end of the pushing and cutting rod is provided with a blade while the other end is a cartoon; one surface of the pushing and cutting rod is fixed with a pick matched with the infant clamp; and one end of the clamp holder is connected with the mother clamp and the infant clamp while an inwall chute at the other end thereof is matched with the pushing and cutting rod. As one end of the clamp holder is manufactured into a big opening, only one end of the clamp holder operates by fingers, the whole operation process can be seen clearly from the big opening; the umbilical cord is clamped by two clamps in advance so as to facilitate the blade to cut; when in operation, the pushing and cutting rod is driven by hands to cut the umbilical cord actively like an injector, thus having easy cut-off and good cutting effect, saving labor, and avoiding blood from sputtering, thereby ensuring physical and psychological health of medical care personnel. The umbilical cord is clamped at first and then the blade is moved to cut, so the length of the reserved umbilical head can be short so as to shorten the drying time thereof, accelerate drop of umbilical head and avoid infection risk induced by the overlong reserved umbilical head.

A fixing structure of bone screws and a connecting rod for a minimally invasive surgery contains: a rigid sleeve having a receiving space, two slots, and a through hole, the receiving space and the through hole being defined on two ends of the rigid sleeve, and the two slots being formed on two opposite sides of an outer wall of the rigid sleeve and communicate with the receiving space; a flexible column being circular and retained in the receiving space of the rigid sleeve. Thereby, a complete rigid limitation and partial flexible limitations generate between at least one bone screw, hence only a tiny opening is cut in the minimally invasive surgery to facilitate surgery recovery and to lower infection risk.

The invention discloses a flexible microneedle drug delivery patch containing a separable drug capsule suitable for transdermal delivery of multiple drugs. The microneedle drug delivery patch has the advantages that pain level is low, infection risk is low and application is convenient. The microneedle drug delivery patch comprises the separable and replaceable drug capsule, a drug carrying end integrating a microneedle array with a microfluid flow passage network, a drug delivering end integrating the microneedle array with the microfluid flow passage network, and a sticky patch body allowing the microneedle drug delivery patch to be attached to skin, wherein the sticky patch body is made from a flexible polymer and is high in curvature and skin bonding property. In use, the drug delivery patch is attached to a joint of a user, the drug carrying end and the drug capsule of the drug delivery patch deform under the squeezing and stretching actions of the bent joint on the flexible microneedle drug delivery patch, so that a syringe needle at the drug carrying end pierces into the drug capsule and drugs are distributed to the drug delivering end through the microfluid flow passage network, and then drugs flow into the body through a passage formed on skin by a microneedle at the drug delivering end to finish drug delivery.

The invention discloses a puncture device causing less pain. The puncture device comprises a blood taking needle, a rod head, a rod body and a tail rod, wherein the rod head is fixed to the front end of the rod body; the tail rod is arranged at the back end of the rod body; an ejection assembly is arranged in the rod body; a needle seat is movably connected in the rod head; a handle rod of the blood taking needle is connected in the needle seat; the front end of an ejection rod in the ejection assembly is over against a carrier rod communicated with the back end of the needle seat. In the puncture device causing less pain having the structure, the ejection device is separated from the needle seat of the blood taking needle, thereby interrupting deviation shake caused by ejection of the ejection device in the transmission process of the needle seat, preventing the phenomenon of shake or deviation of the blood taking needle in a skin contact process, and reducing pain of a patient. Moreover, by improving an indicating sleeve and the tail rod, the infection risk of an operator is further lowered, the operation efficiency is increased, and the manufacturing cost is reduced.

The invention provides an epidemic situation propagation tracking method and system. The method is based on space-time big data and artificial intelligence technology, a research method which integrates new coronal pneumonia individual attack risk factors and a personal close contact dynamic relation network is adopted, and a more comprehensive personal infection risk assessment model is constructed. According to the method, the real-time data mining technology and the knowledge graph technology are combined, and the personnel space-time relation graph is constructed, so that dynamic management of close contact relations of infected persons and cross-department knowledge fusion can be realized. Meanwhile, an infectious disease model is applied to a dynamic personnel relation map with a local community structure and is combined with epidemiological investigation and research, and the personal close contact relation between individual attack risk factors and individuals is comprehensively considered, so that scientific, rapid, accurate and dynamic personal infection risk assessment and modeling prediction are realized; therefore, potential infected persons with high risk can be found as soon as possible, and the epidemic situation prevention and control management capability can be improved.

The invention relates to the therapeutic use of a second generation immunomodulatory oligonucleotide in combination with HIV-1 antigen or immunogen to enhance the ability to reduce the risk HIV infection and to control the progression of HIV infection to prevent AIDS Related Complex (ARC) and AIDS.

The invention discloses a monoclonal antibody of a blood coagulation factor IX. The antibody comprises a light chain and a heavy chain, wherein the variable region amino acid sequence of the light chain is represented by SEQ ID NO.3, and the variable region amino acid sequence of the heavy chain is represented by SEQ ID NO.4. The invention also discloses a preparation method of the antibody. The antibody can specifically identify the blood coagulation factor IX. The invention further discloses a method for purifying the blood coagulation factor IX from blood plasma through utilizing the antibody. The blood coagulation factor IX can be conveniently and efficiently purified from the blood plasma through utilizing the antibody, so the infection risks of the diseases comprising hepatitis A, the hepatitis B, AIDS and the like caused by the patient blood transfusion supplementation of the blood coagulation factor IX are reduced.

The present invention relates generally to an antibacterial coating which is composed of silver, to medical tools and to implants comprising such a coating and to a method as well to an apparatus for the production of such a coating. The medical tools or the dental or orthopaedic implant comprises a metal or metal alloy having a treated surface wherein the treated surface is at least partially converted to an oxide film by plasma electrolytic oxidation using a colloid-dispersed system and wherein the converted surface is partially covered by islands formed by colloid-dispersed silver-particles of the colloid-dispersed system. An Ag—TiO₂ coating shows excellent properties in terms of antibacterial efficacy (even against multi-resistant strains), adhesion and biocompatibility. The life-time of an implant in a human body is increased. The antibacterial coating can be used in the field of traumatology, orthopaedic, osteosynthesis and/or endoprothesis, especially where high infection risk exists.